Report of the key opinion leaders meeting on stem cell-derived beta cells

Jon Odorico; James Markmann; Douglas Melton; Julia Greenstein; Albert Hwa; Cristina Nostro; Alireza Rezania; Jose Oberholzer; Daniel Pipeleers; Luhan Yang; Chad Cowan; Danwei Huangfu; Dieter Egli; Uri Ben-David; Ludovic Vallier; Shane T Grey; Qizhi Tang; Bart Roep; Camilo Ricordi; Ali Naji; Giuseppe Orlando; Daniel G Anderson; Mark Poznansky; Barbara Ludwig; Alice Tomei; Dale L Greiner; Melanie Graham; Melissa Carpenter; Giovanni Migliaccio; Kevin D'Amour; Bernhard Hering; Lorenzo Piemonti; Thierry Berney; Mike Rickels; Thomas Kay; Ann Adams

doi:10.1097/TP.0000000000002217

Report of the key opinion leaders meeting on stem cell-derived beta cells

Jon Odorico, James Markmann, Douglas Melton, Julia Greenstein, Albert Hwa, Cristina Nostro, Alireza Rezania, Jose Oberholzer, Daniel Pipeleers, Luhan Yang, Chad Cowan, Danwei Huangfu, Dieter Egli, Uri Ben-David, Ludovic Vallier, Shane T Grey, Qizhi Tang, Bart Roep, Camilo Ricordi, Ali NajiGiuseppe Orlando, Daniel G Anderson, Mark Poznansky, Barbara Ludwig, Alice Tomei, Dale L Greiner, Melanie Graham, Melissa Carpenter, Giovanni Migliaccio, Kevin D'Amour, Bernhard Hering, Lorenzo Piemonti, Thierry Berney, Mike Rickels, Thomas Kay, Ann Adams

Onderzoeksoutput: Article › peer review

68 Citaten (Scopus)

Samenvatting

Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.

Originele taal-2	English
Pagina's (van-tot)	1223-1229
Aantal pagina's	7
Tijdschrift	Transplantation
Volume	102
Nummer van het tijdschrift	8
DOI's	https://doi.org/10.1097/TP.0000000000002217
Status	Published - aug 2018

Toegang tot document

10.1097/TP.0000000000002217

Andere bestanden en links

Link to publication in Scopus

Citeer dit

Odorico, J., Markmann, J., Melton, D., Greenstein, J., Hwa, A., Nostro, C., Rezania, A., Oberholzer, J., Pipeleers, D., Yang, L., Cowan, C., Huangfu, D., Egli, D., Ben-David, U., Vallier, L., Grey, S. T., Tang, Q., Roep, B., Ricordi, C., ... Adams, A. (2018). Report of the key opinion leaders meeting on stem cell-derived beta cells. Transplantation, 102(8), 1223-1229. https://doi.org/10.1097/TP.0000000000002217

Odorico, Jon ; Markmann, James ; Melton, Douglas ; Greenstein, Julia ; Hwa, Albert ; Nostro, Cristina ; Rezania, Alireza ; Oberholzer, Jose ; Pipeleers, Daniel ; Yang, Luhan ; Cowan, Chad ; Huangfu, Danwei ; Egli, Dieter ; Ben-David, Uri ; Vallier, Ludovic ; Grey, Shane T ; Tang, Qizhi ; Roep, Bart ; Ricordi, Camilo ; Naji, Ali ; Orlando, Giuseppe ; Anderson, Daniel G ; Poznansky, Mark ; Ludwig, Barbara ; Tomei, Alice ; Greiner, Dale L ; Graham, Melanie ; Carpenter, Melissa ; Migliaccio, Giovanni ; D'Amour, Kevin ; Hering, Bernhard ; Piemonti, Lorenzo ; Berney, Thierry ; Rickels, Mike ; Kay, Thomas ; Adams, Ann. / Report of the key opinion leaders meeting on stem cell-derived beta cells. In: Transplantation. 2018 ; Vol. 102, Nr. 8. blz. 1223-1229.

@article{05ebba671b9748418d7bc24783b7e163,

title = "Report of the key opinion leaders meeting on stem cell-derived beta cells",

abstract = "Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.",

keywords = "Animals, Boston, Cell Differentiation, Congresses as Topic, Diabetes Mellitus, Type 1/therapy, Gene Editing, Humans, Immune Tolerance, Insulin-Secreting Cells/cytology, Islets of Langerhans Transplantation, Pancreas Transplantation/methods, Pancreas/cytology, Pluripotent Stem Cells/cytology, Stem Cell Transplantation/methods, Tissue Donors",

author = "Jon Odorico and James Markmann and Douglas Melton and Julia Greenstein and Albert Hwa and Cristina Nostro and Alireza Rezania and Jose Oberholzer and Daniel Pipeleers and Luhan Yang and Chad Cowan and Danwei Huangfu and Dieter Egli and Uri Ben-David and Ludovic Vallier and Grey, {Shane T} and Qizhi Tang and Bart Roep and Camilo Ricordi and Ali Naji and Giuseppe Orlando and Anderson, {Daniel G} and Mark Poznansky and Barbara Ludwig and Alice Tomei and Greiner, {Dale L} and Melanie Graham and Melissa Carpenter and Giovanni Migliaccio and Kevin D'Amour and Bernhard Hering and Lorenzo Piemonti and Thierry Berney and Mike Rickels and Thomas Kay and Ann Adams",

year = "2018",

month = aug,

doi = "10.1097/TP.0000000000002217",

language = "English",

volume = "102",

pages = "1223--1229",

journal = "Transplantation",

issn = "0041-1337",

publisher = "Lippincott Williams and Wilkins",

number = "8",

}

Odorico, J, Markmann, J, Melton, D, Greenstein, J, Hwa, A, Nostro, C, Rezania, A, Oberholzer, J, Pipeleers, D, Yang, L, Cowan, C, Huangfu, D, Egli, D, Ben-David, U, Vallier, L, Grey, ST, Tang, Q, Roep, B, Ricordi, C, Naji, A, Orlando, G, Anderson, DG, Poznansky, M, Ludwig, B, Tomei, A, Greiner, DL, Graham, M, Carpenter, M, Migliaccio, G, D'Amour, K, Hering, B, Piemonti, L, Berney, T, Rickels, M, Kay, T & Adams, A 2018, 'Report of the key opinion leaders meeting on stem cell-derived beta cells', Transplantation, vol. 102, nr. 8, blz. 1223-1229. https://doi.org/10.1097/TP.0000000000002217

Report of the key opinion leaders meeting on stem cell-derived beta cells. / Odorico, Jon; Markmann, James; Melton, Douglas; Greenstein, Julia; Hwa, Albert; Nostro, Cristina; Rezania, Alireza; Oberholzer, Jose; Pipeleers, Daniel; Yang, Luhan; Cowan, Chad; Huangfu, Danwei; Egli, Dieter; Ben-David, Uri; Vallier, Ludovic; Grey, Shane T; Tang, Qizhi; Roep, Bart; Ricordi, Camilo; Naji, Ali; Orlando, Giuseppe; Anderson, Daniel G; Poznansky, Mark; Ludwig, Barbara; Tomei, Alice; Greiner, Dale L; Graham, Melanie; Carpenter, Melissa; Migliaccio, Giovanni; D'Amour, Kevin; Hering, Bernhard; Piemonti, Lorenzo; Berney, Thierry; Rickels, Mike; Kay, Thomas; Adams, Ann.

In: Transplantation, Vol. 102, Nr. 8, 08.2018, blz. 1223-1229.

Onderzoeksoutput: Article › peer review

TY - JOUR

T1 - Report of the key opinion leaders meeting on stem cell-derived beta cells

AU - Odorico, Jon

AU - Markmann, James

AU - Melton, Douglas

AU - Greenstein, Julia

AU - Hwa, Albert

AU - Nostro, Cristina

AU - Rezania, Alireza

AU - Oberholzer, Jose

AU - Pipeleers, Daniel

AU - Yang, Luhan

AU - Cowan, Chad

AU - Huangfu, Danwei

AU - Egli, Dieter

AU - Ben-David, Uri

AU - Vallier, Ludovic

AU - Grey, Shane T

AU - Tang, Qizhi

AU - Roep, Bart

AU - Ricordi, Camilo

AU - Naji, Ali

AU - Orlando, Giuseppe

AU - Anderson, Daniel G

AU - Poznansky, Mark

AU - Ludwig, Barbara

AU - Tomei, Alice

AU - Greiner, Dale L

AU - Graham, Melanie

AU - Carpenter, Melissa

AU - Migliaccio, Giovanni

AU - D'Amour, Kevin

AU - Hering, Bernhard

AU - Piemonti, Lorenzo

AU - Berney, Thierry

AU - Rickels, Mike

AU - Kay, Thomas

AU - Adams, Ann

PY - 2018/8

Y1 - 2018/8

N2 - Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.

AB - Beta cell replacement has the potential to restore euglycemia in patients with insulin-dependent diabetes. Although great progress has been made in establishing allogeneic islet transplantation from deceased donors as the standard of care for those with the most labile diabetes, it is also clear that the deceased donor organ supply cannot possibly treat all those who could benefit from restoration of a normal beta cell mass, especially if immunosuppression were not required. Against this background, the International Pancreas and Islet Transplant Association in collaboration with the Harvard Stem Cell Institute, the Juvenile Diabetes Research Foundation (JDRF), and the Helmsley Foundation held a 2-day Key Opinion Leaders Meeting in Boston in 2016 to bring together experts in generating and transplanting beta cells derived from stem cells. The following summary highlights current technology, recent significant breakthroughs, unmet needs and roadblocks to stem cell-derived beta cell therapies, with the aim of spurring future preclinical collaborative investigations and progress toward the clinical application of stem cell-derived beta cells.

KW - Animals

KW - Boston

KW - Cell Differentiation

KW - Congresses as Topic

KW - Diabetes Mellitus, Type 1/therapy

KW - Gene Editing

KW - Humans

KW - Immune Tolerance

KW - Insulin-Secreting Cells/cytology

KW - Islets of Langerhans Transplantation

KW - Pancreas Transplantation/methods

KW - Pancreas/cytology

KW - Pluripotent Stem Cells/cytology

KW - Stem Cell Transplantation/methods

KW - Tissue Donors

UR - http://www.scopus.com/inward/record.url?scp=85050670486&partnerID=8YFLogxK

U2 - 10.1097/TP.0000000000002217

DO - 10.1097/TP.0000000000002217

M3 - Article

C2 - 29781950

VL - 102

SP - 1223

EP - 1229

JO - Transplantation

JF - Transplantation

SN - 0041-1337

IS - 8

ER -

Report of the key opinion leaders meeting on stem cell-derived beta cells

Samenvatting

Toegang tot document

Andere bestanden en links

Vingerafdruk

Citeer dit